E-MAIL UPDATES

Click here to join

Press releases.

Press releases 2022

Press releases 2022
June 27th 2022

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

June 4th 2022

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

June 2nd 2022

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

May 27th 2022

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

May 4th 2022

Immutep Presents New and Significant Data from the AIPAC Study

April 29th 2022

Immutep Quarterly Activities Report

April 28th 2022

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

March 30th 2022

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

March 24th 2022

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

March 18th 2022

Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022

March 18th 2022

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

March 10th 2022

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

February 25th 2022

Immutep Appoints Lucy Turnbull as Non-Executive Director

February 24th 2022

Immutep to Present at Healthcare Investor Conferences

February 18th 2022

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

February 11th 2022

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

January 31st 2022

Immutep to Present at February Investor Conferences

January 25th 2022

Immutep Quarterly Activities Report